UK trimethoprim switch
This article was originally published in The Tan Sheet
Executive Summary
UK's Medicines and Healthcare products Regulatory Agency (MHRA) seeks comments on the Prescription Only Medication (POM) to Pharmacy (P) reclassification of Alpharma Limited's Cysticlear (trimethoprim) 200 mg tablets for treatment of urinary tract infections. The request is not surprising in light of the UK's current switch environment; McNeil Europe VP-R&D Stephen Mann recently predicted trimethoprim would "almost certainly go" POM to P by the end of the year (1"The Tan Sheet," July 4, 2005, p. 11). MHRA asks that comments be submitted by Aug. 16...
You may also be interested in...
European Switches: Germany Looks To Triptans, McNeil Follows Zocor
Germany's Ministry of Health is expected to issue a decision on the nonprescription sale of naratriptan for migraine in January 2006
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.